Cargando…

Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody

Platinum chemotherapy remains part of standard therapies in the management of a variety of cancers. Severe side effects and a high degree of resistance to platinum drugs have led numerous researchers to search for predictive biomarkers, which could aid in identifying patients that are the most likel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, David Hersi, Fiehn, Anne-Marie Kanstrup, Fogh, Louise, Christensen, Ib Jarle, Hansen, Tine Plato, Stenvang, Jan, Nielsen, Hans Jørgen, Nielsen, Kirsten Vang, Hasselby, Jane Preuss, Brünner, Nils, Jensen, Sussie Steen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945488/ https://www.ncbi.nlm.nih.gov/pubmed/24603753 http://dx.doi.org/10.1038/srep04313

Ejemplares similares

An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort
por: Smith, David Hersi, et al.
Publicado: (2013)

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer
por: Illemann, Martin, et al.
Publicado: (2014)

Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
por: Smith, David Hersi, et al.
Publicado: (2013)

Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals
por: Thorsen, Stine Buch, et al.
Publicado: (2013)

Data fusion in metabolomic cancer diagnostics
por: Bro, Rasmus, et al.
Publicado: (2012)

Early Detection and Recurrence of Colorectal Adenomas by Combination of Eight Cancer-Associated Biomarkers in Plasma
por: Rasmussen, Louise, et al.
Publicado: (2020)

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
por: Schrohl, Anne-Sofie, et al.
Publicado: (2011)

Cathepsin X in serum from patients with colorectal cancer: relation to prognosis
por: Vizin, Tjasa, et al.
Publicado: (2012)

High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients
por: Nielsen, Boye Schnack, et al.
Publicado: (2010)

Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue
por: Cederbye, Camilla Natasha, et al.
Publicado: (2016)

Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development
por: Stenvang, Jan, et al.
Publicado: (2013)

Circulating VEGF As a Biological Marker in Patients with Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients
por: Hetland, Merete Lund, et al.
Publicado: (2008)

Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients
por: Vižin, Tjaša, et al.
Publicado: (2014)

Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer
por: Rasmussen, Louise, et al.
Publicado: (2017)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

Screening for colorectal cancer: possible improvements by risk assessment evaluation?
por: Nielsen, Hans J, et al.
Publicado: (2011)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017)

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)

Flow Cytometric Bivariate Analysis of DNA and Cytokeratin in Colorectal Cancer
por: Post, Carolin, et al.
Publicado: (2002)

Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis
por: Dolin, Troels Gammeltoft, et al.
Publicado: (2021)

Age‐stratified reference intervals unlock the clinical potential of circulating cell‐free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer
por: Ørntoft, Mai‐Britt Worm, et al.
Publicado: (2020)

Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer
por: Thorsen, Stine F., et al.
Publicado: (2019)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

A Fatal Case of Primary Basaloid Squamous Cell Carcinoma in the Intrahepatic Bile Ducts
por: Kirkegaard, Johan, et al.
Publicado: (2014)

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
por: Tarpgaard, Line S., et al.
Publicado: (2016)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells
por: Pedraz-Cuesta, Elena, et al.
Publicado: (2015)

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations
por: Jensen, Niels Frank, et al.
Publicado: (2016)

Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer
por: GÓMEZ-DÍAZ, BENJAMÍN, et al.
Publicado: (2015)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development
por: Rouissi, Kamel, et al.
Publicado: (2011)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma
por: Cui, Qing-ke, et al.
Publicado: (2014)

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
por: Buhl, Ida Kappel, et al.
Publicado: (2018)

Hamartomatous polyposis syndromes: A review
por: Jelsig, Anne Marie, et al.
Publicado: (2014)

Multi-detector CT-angiography is useful in predicting haematoma expansion in patients with acute primary intracerebral hemorrhage
por: Havsteen, Inger, et al.
Publicado: (2010)

Comparison of two self-reported measures of physical work demands in hospital personnel: A cross-sectional study
por: Nabe-Nielsen, Kirsten, et al.
Publicado: (2008)

ERCC1 and ERCC2 Haplotype Modulates Induced BPDE-DNA Adducts in Primary Cultured Lymphocytes
por: Lu, Xiaobo, et al.
Publicado: (2013)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mbbpcm5plhvtpae2br7eub1r91